Parallel, divergent or drifting? Regulating healthcare products in a post-Brexit UK

EU laws have exerted a powerful influence on research, manufacturing, supply, sale and procurement of the products which national health systems rely. Pre-Brexit, UK was closely involved in policy operation regulations affecting these goods. Since Brexit, ideological polarisation political salience during global pandemic driven rhetoric competitive divergence. However, active divergence to date is limited. It unsettled whether UK, as small market this industry, genuinely seeks higher risk, more industry-friendly regulatory paradigm. With capacity also under strain, important decisions been delayed. The position Northern Ireland remains highly precarious, with negotiations ongoing how handle its unique partial status within single market. UK’s attempt remain EU’s research funding programme has consequently pushed into involuntary